Cargando…
_version_ 1784577248027738112
author Toda, Masataro G.
Fujii, Kentaro
Kato, Ai
Yoshifuji, Ayumi
Komatsu, Motoaki
Amino, Yoshiaki
Kitazono, Satoru
Hashiguchi, Akinori
Ryuzaki, Munekazu
author_facet Toda, Masataro G.
Fujii, Kentaro
Kato, Ai
Yoshifuji, Ayumi
Komatsu, Motoaki
Amino, Yoshiaki
Kitazono, Satoru
Hashiguchi, Akinori
Ryuzaki, Munekazu
author_sort Toda, Masataro G.
collection PubMed
description
format Online
Article
Text
id pubmed-8484110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84841102021-10-06 Minimal Change Disease Associated With Durvalumab Toda, Masataro G. Fujii, Kentaro Kato, Ai Yoshifuji, Ayumi Komatsu, Motoaki Amino, Yoshiaki Kitazono, Satoru Hashiguchi, Akinori Ryuzaki, Munekazu Kidney Int Rep Letter to the Editor Elsevier 2021-09-01 /pmc/articles/PMC8484110/ /pubmed/34622115 http://dx.doi.org/10.1016/j.ekir.2021.08.021 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Toda, Masataro G.
Fujii, Kentaro
Kato, Ai
Yoshifuji, Ayumi
Komatsu, Motoaki
Amino, Yoshiaki
Kitazono, Satoru
Hashiguchi, Akinori
Ryuzaki, Munekazu
Minimal Change Disease Associated With Durvalumab
title Minimal Change Disease Associated With Durvalumab
title_full Minimal Change Disease Associated With Durvalumab
title_fullStr Minimal Change Disease Associated With Durvalumab
title_full_unstemmed Minimal Change Disease Associated With Durvalumab
title_short Minimal Change Disease Associated With Durvalumab
title_sort minimal change disease associated with durvalumab
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484110/
https://www.ncbi.nlm.nih.gov/pubmed/34622115
http://dx.doi.org/10.1016/j.ekir.2021.08.021
work_keys_str_mv AT todamasatarog minimalchangediseaseassociatedwithdurvalumab
AT fujiikentaro minimalchangediseaseassociatedwithdurvalumab
AT katoai minimalchangediseaseassociatedwithdurvalumab
AT yoshifujiayumi minimalchangediseaseassociatedwithdurvalumab
AT komatsumotoaki minimalchangediseaseassociatedwithdurvalumab
AT aminoyoshiaki minimalchangediseaseassociatedwithdurvalumab
AT kitazonosatoru minimalchangediseaseassociatedwithdurvalumab
AT hashiguchiakinori minimalchangediseaseassociatedwithdurvalumab
AT ryuzakimunekazu minimalchangediseaseassociatedwithdurvalumab